AI-generated analysis. Always verify with the original filing.
Bonus Biogroup Ltd. is a clinical-stage biotechnology company developing next-generation tissue engineering and cell therapy products, primarily BonoFill, a personalized autologous bone graft for bone regeneration, and MesenCure, an allogeneic MSC therapy for respiratory distress including ARDS. BonoFill has completed Phase II for maxillofacial defects and has an ongoing Phase II for limb bone defects; MesenCure completed Phase II for COVID-related respiratory distress and received FDA IND clearance for Phase III in February 2025. The company has no revenue, reported NIS 27.8 million net loss for 2024 (down 2.5% YoY), with NIS 6.9 million cash as of December 31, 2024, and substantial doubt about going concern status. It raised NIS 16.5 million via PIPE transactions in 2025/2026. This F-1/A filing supports an IPO of ADSs (each representing 100 ordinary shares) at an assumed price equivalent to TASE closing, with underwriter option for 15% additional ADSs, proceeds estimated at $ million before expenses. Net proceeds will fund preclinical/early clinical research ($ million), Phase III for MesenCure ($ million), Phase III for BonoFill ($ million), and working capital. The company seeks Nasdaq listing under 'BONS' to fund clinical advancement toward U.S. approvals, leveraging estimated $25B TAM for BonoFill and $9.4B for MesenCure by 2030, despite clinical, financial, and regulatory risks.
Offering Amount
$4.9M
Shares Offered
1,167,925,311
Price Range
$0.50 – $0.60
Issuer Type
from the issuance of the Securities as may be required under Rule 463 under the 1933 Act.</P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"> </P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in">(k) <U>Issuer Free Writing Prospectuses</U>.
Offering Amount
$ million (assumed)
Share Type
American Depositary Shares (ADSs, each representing 100 ordinary shares)
Exchange
Nasdaq Capital Market
Ticker
BONS
Use of Proceeds: Preclinical/early clinical R&D ($M), Phase III MesenCure ($M), Phase III BonoFill ($M), working capital.
Clinical-stage biotechnology company focused on developing next-generation tissue engineering and cell therapy products, including BonoFill (autologous bone graft) and MesenCure (allogeneic cell therapy for inflammation and tissue damage).